Early Asset Evaluation

Opportunity assessments have traditionally been conducted during late-stage clinical development, but they have now become essential even for early-stage product development and portfolio choices. Early horizon scanning and market landscape assessment enable companies to make well-informed decisions and preempt potential clinical and commercial challenges.

 

These assessments offer vital insights into program progress, product line extensions, and partnering decisions, enhancing decision-making for early commercial and Business Development & Licensing (BD&L) teams. Furthermore, when venturing into new disease areas, Svantis' market attractiveness analysis offers a comprehensive perspective on the target market, identifying new opportunities and potential threats in-depth.